Weight loss / metabolic (investigational)

Retatrutide

Triple agonist (GLP-1 + GIP + glucagon)

Investigational — strong Phase 3 data, not yet approved
Based on expert consensus from publicly available videos plus public FDA/regulatory status — not medical advice. Peptides are prescription territory; consult a physician before using anything here.

The Verdict

The most potent GLP-1 on the horizon (~25-30% weight loss in its 2026 Phase 3 trial), but still investigational. Precis's panel hasn't covered it directly — and gray-market vials are a real risk.

The Evidence

FDA / Legal Status

Not FDA-approved (Phase 3 as of mid-2026)

Human Evidence

Phase 3 TRIUMPH-1 (ADA, June 2026): ~25-30% weight loss — but not yet approved

Sport / Doping

Not approved; gray-market versions carry contamination/dosing risk

Safety Flags

  • Not FDA-approved — gray-market supply risks contamination and inaccurate dosing
  • Emerging signals include a resting-heart-rate increase; even more muscle-preservation discipline needed

Who Covers It

Andrew Huberman
Andrew Huberman

Other experts in the panel had no substantive coverage of this peptide — we don't guess their position.

Want the deep dive on Retatrutide?

This grade is free. Pro unlocks chat with the full expert dataset — ask about dosing, stacks, sourcing, and the exact citations behind every claim.

Cancel anytime

Go Deeper

GLP-1 Report Common Question All Peptides
All peptides